1. Home
  2. SBCF vs RVPH Comparison

SBCF vs RVPH Comparison

Compare SBCF & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SBCF

Seacoast Banking Corporation of Florida

HOLD

Current Price

$32.51

Market Cap

3.0B

Sector

Finance

ML Signal

HOLD

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.66

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBCF
RVPH
Founded
1926
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
71.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBCF
RVPH
Price
$32.51
$0.66
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$31.00
$3.33
AVG Volume (30 Days)
593.2K
4.3M
Earning Date
01-26-2026
11-13-2025
Dividend Yield
2.33%
N/A
EPS Growth
23.57
N/A
EPS
1.68
N/A
Revenue
$556,541,000.00
N/A
Revenue This Year
$33.11
N/A
Revenue Next Year
$30.09
N/A
P/E Ratio
$19.39
N/A
Revenue Growth
12.63
N/A
52 Week Low
$21.36
$0.25
52 Week High
$33.23
$2.95

Technical Indicators

Market Signals
Indicator
SBCF
RVPH
Relative Strength Index (RSI) 60.26 58.18
Support Level $31.97 $0.60
Resistance Level $33.17 $0.77
Average True Range (ATR) 0.77 0.05
MACD 0.11 0.01
Stochastic Oscillator 77.92 61.01

Price Performance

Historical Comparison
SBCF
RVPH

About SBCF Seacoast Banking Corporation of Florida

Seacoast Banking Corp of Florida is a holding company for Seacoast National Bank. The company provides integrated financial services including commercial and consumer banking, wealth management, and mortgage and insurance services to customers across Florida, and through mobile and online banking solutions. In addition, it provides services such as treasury management, brokerage and credit facilities.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: